全文获取类型
收费全文 | 155587篇 |
免费 | 11161篇 |
国内免费 | 617篇 |
专业分类
耳鼻咽喉 | 1762篇 |
儿科学 | 3859篇 |
妇产科学 | 2606篇 |
基础医学 | 20435篇 |
口腔科学 | 3384篇 |
临床医学 | 15298篇 |
内科学 | 32727篇 |
皮肤病学 | 3240篇 |
神经病学 | 14392篇 |
特种医学 | 6934篇 |
外国民族医学 | 14篇 |
外科学 | 25039篇 |
综合类 | 1938篇 |
一般理论 | 109篇 |
预防医学 | 11511篇 |
眼科学 | 3273篇 |
药学 | 10072篇 |
中国医学 | 235篇 |
肿瘤学 | 10537篇 |
出版年
2023年 | 805篇 |
2022年 | 586篇 |
2021年 | 3040篇 |
2020年 | 2079篇 |
2019年 | 3118篇 |
2018年 | 3591篇 |
2017年 | 2797篇 |
2016年 | 3135篇 |
2015年 | 3584篇 |
2014年 | 5090篇 |
2013年 | 6847篇 |
2012年 | 10335篇 |
2011年 | 11003篇 |
2010年 | 6307篇 |
2009年 | 6013篇 |
2008年 | 9744篇 |
2007年 | 10187篇 |
2006年 | 10094篇 |
2005年 | 10141篇 |
2004年 | 9307篇 |
2003年 | 8609篇 |
2002年 | 8242篇 |
2001年 | 2123篇 |
2000年 | 1781篇 |
1999年 | 2001篇 |
1998年 | 1654篇 |
1997年 | 1289篇 |
1996年 | 1075篇 |
1995年 | 1215篇 |
1994年 | 1101篇 |
1993年 | 990篇 |
1992年 | 1264篇 |
1991年 | 1186篇 |
1990年 | 1023篇 |
1989年 | 969篇 |
1988年 | 898篇 |
1987年 | 876篇 |
1986年 | 875篇 |
1985年 | 856篇 |
1984年 | 907篇 |
1983年 | 781篇 |
1982年 | 937篇 |
1981年 | 836篇 |
1980年 | 719篇 |
1979年 | 646篇 |
1978年 | 643篇 |
1977年 | 516篇 |
1976年 | 490篇 |
1974年 | 504篇 |
1973年 | 439篇 |
排序方式: 共有10000条查询结果,搜索用时 19 毫秒
1.
2.
Jones type fifth metatarsal fractures pose a challenge to the foot and ankle surgeon, given documented high nonunion rates as well as high complication rates including hardware prominence, nerve injury, and screw breakage for existing treatment modalities including screw and plantar plate fixation. We call for the design of innovative Jones-fracture specific implants which contour to the natural curve of the fifth metatarsal. Future research should aim to expand upon existing literature for Jones fracture fixation and evaluate efficacy of novel implants which are designed to address unacceptably high complication rates for existing treatment modalities. 相似文献
3.
S. Harrogate J. Barnes K. Thomas A. Isted G. Kunst S. Gupta S. Rudd T. Banerjee R. Hinchliffe R. Mouton 《Anaesthesia》2023,78(11):1393-1408
Tobacco smoking is associated with a substantially increased risk of postoperative complications. The peri-operative period offers a unique opportunity to support patients to stop tobacco smoking, avoid complications and improve long-term health. This systematic review provides an up-to-date summary of the evidence for tobacco cessation interventions in surgical patients. We conducted a systematic search of randomised controlled trials of tobacco cessation interventions in the peri-operative period. Quantitative synthesis of the abstinence outcomes data was by random-effects meta-analysis. The primary outcome of the meta-analysis was abstinence at the time of surgery, and the secondary outcome was abstinence at 12 months. Thirty-eight studies are included in the review (7310 randomised participants) and 26 studies are included in the meta-analysis (5969 randomised participants). Studies were pooled for subgroup analysis in two ways: by the timing of intervention delivery within the peri-operative period and by the intensity of the intervention protocol. We judged the quality of evidence as moderate, reflecting the degree of heterogeneity and the high risk of bias. Overall, peri-operative tobacco cessation interventions increased successful abstinence both at the time of surgery, risk ratio (95%CI) 1.48 (1.20–1.83), number needed to treat 7; and 12 months after surgery, risk ratio (95%CI) 1.62 (1.29–2.03), number needed to treat 9. More work is needed to inform the design and optimal delivery of interventions that are acceptable to patients and that can be incorporated into contemporary elective and urgent surgical pathways. Future trials should use standardised outcome measures. 相似文献
4.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
5.
Robert J. Motzer MD David F. McDermott MD Bernard Escudier MD Mauricio Burotto MD Toni K. Choueiri MD Hans J. Hammers MD PhD Philippe Barthélémy MD PhD Elizabeth R. Plimack MD Camillo Porta MD Saby George MD Thomas Powles MD Frede Donskov MD PhD Howard Gurney MD Christian K. Kollmannsberger MD Marc-Oliver Grimm MD Carlos Barrios MD Yoshihiko Tomita MD PhD Daniel Castellano MD Viktor Grünwald MD PhD Brian I. Rini MD M. Brent McHenry PhD Chung-Wei Lee MD PhD Jennifer McCarthy MA Flavia Ejzykowicz PhD Nizar M. Tannir MD 《Cancer》2022,128(11):2085-2097
6.
Helmer Philipp Schlesinger Tobias Hottenrott Sebastian Papsdorf Michael Wöckel Achim Diessner Joachim Stumpner Jan Sitter Magdalena Skazel Tobias Wurmb Thomas Härtel Christoph Hofer Stefan Alkatout Ibrahim Girard Thierry Meybohm Patrick Kranke Peter 《Der Anaesthesist》2022,71(3):171-180
Die Anaesthesiologie - Die Implementierung eines Patient Blood Management (PBM) wird zunehmender Standard in der operativen Medizin. Seit einiger Zeit gilt das Interesse auch den vulnerablen... 相似文献
7.
8.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
9.
Kerstin Folkerts Natalia Petruski-Ivleva Erin Comerford Michael Blankenburg Thomas Evers Alain Gay Linda Fried Csaba P. Kovesdy 《Mayo Clinic proceedings. Mayo Clinic》2021,96(4):975-986
ObjectiveTo examine the screening rates for kidney damage and function among patients with type 2 diabetes (T2D) and chronic kidney disease stage at diabetes diagnosis using a US administrative claims database.Patients and MethodsThis cohort study used a claims database enriched with laboratory results data. Patients with T2D (defined as 1 inpatient or 2 outpatient claims for diabetes), aged 18 years or older, and with at least 1 year of follow-up enrollment were identified. Patients with type 1 diabetes, kidney disease, or other related conditions at baseline were excluded. We estimated screening rates using laboratory orders for serum creatinine and estimated glomerular filtration rate (eGFR) measurement and urine albumin to creatinine ratio (UACR). Chronic kidney disease severity was reported using the Kidney Disease: Improving Global Outcomes classification based on laboratory results.ResultsA total of 1,881,447 patients with T2D were eligible for analysis. Mean ± SD age was 63.1±13.1 years; 947,150 patients (50.3%) were male. Serum creatinine tests were ordered within 14 days of the index date among 290,722 patients of 622,915 (46.7%) patients with newly-recognized T2D. Overall, 1,595,964 patients (84.8%) had at least one serum creatinine test ordered during the 1-year follow-up period. Fewer patients received a UACR test during follow-up (814,897 [43.3%]). Less than half of all patients with T2D received a laboratory test order for both serum creatinine and urine albumin measurements during the follow-up period.ConclusionPhysicians treating patients with diabetes are selectively adhering to chronic kidney disease screening guidelines, as indicated by high rates of eGFR testing, but less frequent UACR testing. Despite recommendations to monitor both eGFR and UACR, less than half of patients were screened for albuminuria during the 1-year follow-up. 相似文献
10.